Intervacc Investor Relations Material
Intervacc AB, a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. The company offers Canvax, a vaccine for bovine viral diarrhea; and Fervac B, a vaccine for feline viral rhinotracheitis, calicivirus, and panleukopenia. It also provides a range of potential prevention vaccines to veterinarians, including vaccines to control rabies. Intervacc is based in Hägersten, Sweden
Upcoming events for
Q3 20222022-11-10
Q2 20222022-08-31
Latest company events
Ticker symbol
IVACC
Country
Sweden
About the company
Investor Relations Page
Dig deeper into the Intervacc fundamentals on Quartr.
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
